Afatinib (A) versus chemotherapy (CT) for EGFR mutation-positive NSCLC patients (pts) aged >= 65 years: Subgroup analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)

臺大醫院-腫瘤醫學部;臺大醫學院-腫瘤醫學研究所;Wu, Y. -L.Y. -L.WuSequist, L. V.L. V.SequistGeater, S. L.S. L.GeaterOrlov, S.S.OrlovLee, K. H.K. H.LeeTsai, C. -M.C. -M.TsaiKato, T.T.KatoKiura, K.K.KiuraBarrios, C. H.C. H.BarriosSchuler, M.M.SchulerHirsh, V.V.HirshYamamoto, N.N.YamamotoO'Byrne, K.K.O'ByrneMok, T.T.MokMassey, D.D.MasseyMaerten, A.A.MaertenYang, J. C. -H.J. C. -H.Yang2017-06-272018-07-092017-06-272018-07-092015http://ntur.lib.ntu.edu.tw//handle/246246/280173Afatinib (A) versus chemotherapy (CT) for EGFR mutation-positive NSCLC patients (pts) aged >= 65 years: Subgroup analyses of LUX-Lung 3 (LL3) and LUX-Lung 6 (LL6)